Wegovy vs Zepbound: the head-to-head, honestly read

Tirzepatide activates GIP alongside GLP-1. The dual signal appears to deepen appetite suppression and metabolic effects beyond what GLP-1 alone achieves at tolerable doses, which is the going explanation for the consistent gap across programs, not just the head-to-head.

Deeper average effect does not mean deeper effect for every person: response distributions are wide and overlapping, and non-response to one molecule does not predict non-response to the other.

Not reliably. Both lead with nausea, diarrhea, constipation, and vomiting concentrated during dose escalation; the head-to-head reported broadly comparable rates and discontinuations. Cross-trial numbers (Wegovy's ~44% nausea in STEP 1 vs Zepbound's ~25–30% in SURMOUNT-1) tempt a verdict, but different trials measure differently; the direct comparison found them similar.

Individually, people genuinely differ, in both directions. If one treats you roughly at every step despite good mechanics, that experience, logged, is a legitimate reason to discuss the other.

Coverage and price: formularies often prefer one, and the out-of-pocket difference can dwarf the efficacy difference. Supply: availability still fluctuates by dose and region. History: semaglutide carries the longer record and a cardiovascular outcomes label from SELECT, which matters for some risk profiles; tirzepatide holds the sleep-apnea label and the strongest averages.

And the quiet decider: which routine you will actually sustain. A medication is a multi-year relationship; the one you stay on beats the one that averaged better in someone else's trial.

The class red flags apply identically: severe persistent abdominal pain (pancreatitis territory), right-sided pain after fatty meals (gallbladder), vomiting past 24 hours (dehydration), hypoglycemia when combined with insulin or sulfonylureas, and the thyroid C-cell exclusion for MTC or MEN2 history. Both stop before pregnancy.

Our dedicated Wegovy and Zepbound side-effect guides carry each product's full numbers, timelines, and management playbooks.

Work the order that reality imposes: coverage and price first, medical history second (your prescriber weighs the outcome labels against your profile), then desired effect size, then tolerability as lived, not as feared. Whichever you start, judge it on your own trend after reaching a therapeutic dose.

Switching is routine in both directions, usually landing at a low or middle step of the new ladder rather than the top. A few weeks of dose, side-effect, and trend records in DoseLog turns the switch conversation from vibes into a documented decision.